

503 **Table S1.** Probabilities of achieving $f\%T>MIC$ targets by MIC following administration
 504 of 600 mg ceftaroline fosamil q12h for patients with normal renal function and mild renal
 505 impairment

Percentage of simulated patients achieving $f\%T>MIC$ targets				
MIC (mg/L)	$f\%T>MIC$ targets for <i>S. aureus</i> of $\geq 26/\geq 36/\geq 51$		$f\%T>MIC$ targets for <i>S. pneumoniae</i> of $\geq 35/\geq 44/\geq 51$	
	Normal renal function	Mild renal impairment	Normal renal function	Mild renal impairment
0.125	100/100/100	100/100/100	100/100/100	100/100/100
0.25	100/100/99.8	100/100/100	100/100/99.8	100/100/100
0.5	100/99.8/97.1	100/100/99.7	99.8/99.2/97.1	100/100/99.7
1	99.7/97.9/76.2	100/99.9/94.1	98.3/90.6/76.2	99.9/98.3/94.1
2	95.9/74.5/28.8	99.5/93.5/63.5	79.1/49.6/28.8	95.2/80.3/63.5
4	46.8/14.6/2.15	77.2/43.2/13.2	18.4/5.15/2.15	48.9/24.9/13.2
8	0.65/0/0	6.15/1.2/0.05	0/0/0	1.50/0.40/0.05
16	0/0/0	0/0/0	0/0/0	0/0/0

506 **Table S2.** Percentage of simulated patients with moderate renal impairment achieving *f %T>MIC* targets by MIC following
 507 administration of various ceftaroline fosamil dosing regimens

MIC (mg/L)	Percentage of simulated patients achieving <i>f %T>MIC</i> targets							
	<i>f %T>MIC</i> targets for <i>S. aureus</i> of $\geq 26/\geq 36/\geq 51$				<i>f %T>MIC</i> targets for <i>S. pneumoniae</i> of $\geq 35/\geq 44/\geq 51$			
	300 mg q12h	400 mg q12h	600 mg q12h	600 mg q24h	300 mg q12h	400 mg q12h	600 mg q12h	600 mg q24h
0.125	100/100/100	100/100/100	100/100/100	100/100/97.8	100/100/100	100/100/100	100/100/100	100/99.5/97.8
0.25	100/100/99.7	100/100/99.9	100/100/100	100/99.4/87.1	100/100/99.7	100/100/100	100/100/100	99.6/95.8/87.1
0.5	100/99.8/94.6	100/99.9/98.7	100/100/99.9	99.8/93.8/60.5	99.9/98.5/94.6	100/99.9/98.7	100/100/100	95.6/80.7/60.5
1	99.4/92.5/62.4	99.9/99.1/86.8	100/99.9/98.4	96.5/74.1/25.7	94.6/79.9/62.4	99.3/95.2/86.8	100/99.8/98.4	77.8/45.3/25.7
2	73.8/38.7/10.4	96.1/78.1/38.8	99.9/98.0/83.2	73.1/29.9/3.35	43.5/21.1/10.4	81.4/57.7/38.8	98.7/93.4/83.2	34.4/10.2/3.35
4	3.2/0.40/0	32.9/12.8/2.25	91.5/68.6/32.3	13.7/1.0/0.15	0.60/0.15/0	14.7/5.80/2.25	73.0/48.3/32.3	1.40/0.35/0.15
8	0/0/0	0.15/0/0	19.2/7.60/1.70	0/0/0	0/0/0	0/0/0	8.80/3.45/1.70	0/0/0
16	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0

508

509 **Table S3.** Percentage of simulated patients with severe renal impairment achieving *f* %T>MIC targets by MIC following
 510 administration of various ceftaroline fosamil dosing regimens

MIC (mg/L)	Percentage of simulated patients achieving <i>f</i> %T>MIC targets									
	<i>f</i> %T>MIC targets for <i>S. aureus</i> of ≥26/≥36/≥51					<i>f</i> %T>MIC targets for <i>S. pneumoniae</i> of ≥35/≥44/≥51				
	300 mg q12h	400 mg q12h	600 mg q12h	600 mg q24h	800 mg q24h	300 mg q12h	400 mg q12h	600 mg q12h	600 mg q24h	800 mg q24h
0.125	100/100/100	100/100/100	100/100/100	100/100/99.6	100/100/99.9	100/100/100	100/100/100	100/100/100	100/100/99.6	100/100/100
0.25	100/100/99.9	100/100/100	100/100/100	100/99.9/97.2	100/100/99.3	100/100/100	100/100/100	100/100/100	100/99.4/97.2	100/99.8/99.3
0.5	100/99.9/99.0	100/100/99.9	100/100/100	100/99.0/86.7	100/99.8/94.7	100/99.9/99.0	100/100/99.9	100/100/100	99.3/94.3/86.7	99.9/98.6/94.7
1	99.9/98.6/87.5	100/99.9/97.0	100/100/99.9	99.4/92.4/59.2	100/98.1/80.6	99.0/95.0/87.5	99.9/99.3/97.0	100/99.9/99.9	93.9/77.5/59.2	98.4/91.6/80.6
2	92.2/72.3/39.0	99.3/94.1/73.0	100/99.9/96.0	92.4/63.6/23.1	98.6/86.9/48.3	77.2/54.5/39.0	95.4/84.6/73.0	99.9/98.7/96.0	67.9/39.0/23.1	89.2/67.6/48.3
4	22.0/9.85/2.85	66.2/40.2/19.3	98.1/89.8/67.6	44.4/13.7/1.9	82.2/47.4/12.3	11.5/5.95/2.85	44.2/28.2/19.3	92.1/79.1/67.6	16.2/4.75/1.90	50.3/24.9/12.3
8	0.10/0.05/0	4.05/1.70/0.45	48.0/30.5/17.4	0.95/0.15/0.10	15.6/3.55/0.45	0/0/0	1.80/0.85/0.45	33.1/23.1/17.4	0.20/0.10/0.10	3.90/1.05/0.45
16	0/0/0	0/0/0	1.50/0.60/0.15	0/0/0	0/0/0	0/0/0	0/0/0	0.75/0.30/0.15	0/0/0	0/0/0

511